ここがポイント！　糖尿病とNAFLD/NASH

出版社： 医学と看護社
著者：
発行日： 2018-09-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784906829910
電子書籍版： 2018-09-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,850 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,850 円(税込)

購入する

商品紹介

増加し続ける糖尿病とNAFLD/NASHの深い関係からその治療法までを明解に説く！

目次

  • はじめに
    第1章　NAFLD/NASHとは
    １．分類
    第2章　NAFLDからNASHへ─進展と予後─
    第3章　NAFLD/NASHリスクとしての糖代謝障害
    １．内臓脂肪型肥満、メタボリック症候群
    ２．2型糖尿病
    第4章　NAFLD/NASHの病因・病態
    １．二次性NAFLD/NASH
    ２．遺伝的素因
    ３．Multiple Parallel Hits Hypothesis―分子学的発症機序（基礎研究）―
    ４．肝での選択的インスリン抵抗性
    第5章　NAFLD/NASHの検査法
    １．肝脂肪化の評価
    ２．NASHの鑑別、状態を評価する検査
    ３．肝線維化の評価
    第6章　NAFLD/NASHの治療法
    １．食事・運動・行動療法
    ２．内科治療薬（現在と未来）
    ３．外科治療（減量手術）
    さいごに

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

引用文献

P.56 掲載の参考文献
1) Kojima S, Watanabe N, Numata M, et al : Increase in the prevalence of fatty liver in Japan over the past 12 years : analysis of clinical background. J Gastroenterol 2003 ; 38 : 954-61
 
2) 岡上武, ほか : NAFLDの疫学, 日本肝臓学会編, NASH・NAFLDの診療ガイド 2015,文光堂 ; 2015
 
3) 日本消化器病学会編 : NAFLD/NASH診療ガイドライン 2014, 南江堂 ; 2014
 
4) アルコール医学生物学研究会編 : ASBRAアルコール性肝障害診断基準 (2011年版), アルコール医学生物学研究会, 旭川 ; 2012
 
5) Ludwig J, Viggiano TR, McGill DB, et al : Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980 ; 55 : 434-8
 
6) Eguchi Y, Hyogo H, Ono M, et al : Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan : a multicenter large retrospective study. J Gastroenterol 2012 ; 47 : 586-95
 
7) Yatsuji S, Hashimoto E, Tobari M, et al : Influence of age and gender in Japanese patients with nonalcoholic steatohepatitis. Hepatol Res 2007 ; 37 : 1034-4
PubMed
8) Musso G, Gambino R, Cassader M, et al : Meta-analysis : natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011 ; 43 : 617-49
 
9) Adams LA, Lymp JF, St Sauver J, et al : The natural history of nonalcoholic fatty liver disease : a population-based cohort study. Gastroenterology 2005 ; 129 : 113-21
 
10) Yatsuji S, Hashimoto E, Tobari M, et al : Influence of age and gender in Japanese patients with nonalcoholic steatohepatitis. Hepatol Res 2007 ; 37 : 1034-43
 
11) 日本肥満学会編 : 肥満症診療ガイドライン 2016, ライフサイエンス出版 ; 2016
 
12) Strissel KJ, Stancheva Z, Miyoshi H, et al : Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007 ; 56 : 2910-8
 
13) Takeno K, Tamaru Y, Kawaguchi M, et al : Relation Between Insulin Sensitivity and Metabolic Abnormalities in Japanese Men With BMI of 23-25 kg/m2. J Clin Endocrinol Metab 2016 ; 101 : 3676-84
 
14) Yonemoto K, Doi Y, Hata J, Ninomiya T, et al : Body mass index and stroke incidence in a Japanese community : the Hisayama study. Hypertens Res 2011 ; 34 : 274-9
 
15) Araneta MR, Kanaya AM, Hsu WC, et al : Optimum BMI cut points to screen asian americans for type 2 diabetes. Diabetes Care 2015 ; 38 : 814-20
 
16) Tatsumi K, Saibara T : Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis. Hepatol Res 2005 ; 33 : 100-4
 
17) Jimba S, Nakagami T, Takahashi M, et al : Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005 ; 22 : 1141-5
 
18) Doi Y, Kubo M, Yonemoto K, et al : Liver enzymes as a predictor for incident diabetes in a Japanese population : the Hisayama study. Obesity 2007 ; 15 : 1841-50
 
19) Ballestri S, Zona S, Targher G, et al : Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016 ; 31 : 936-44
 
20) Fukuda T, Hamaguchi M, Kojima T, et al : The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016 ; 36 : 275-83
 
21) 篁俊成, ほか : 脂肪肝と糖尿病のクロストーク. 糖尿病の最新治療 2017 ; 8 (2)
Medical*Online
22) Kawamura Y, Arase Y, Ikeda K, et al : Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012 ; 107 : 253-61
 
23) Shima T, Seki K, Umemura A, et al : Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol Res 2015 ; 45 : 548-59
 
24) Nakahara T, Hyogo H, Yoneda M, et al ; Japan Study Group of Nonalcoholic Fatty Liver Disease : Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2014 ; 49 : 1477-84
 
25) Loomba R, Abraham M, Unalp A, et al ; Nonalcoholic Steatohepatitis Clinical Research Network : Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012 ; 56 : 943-51
PubMed
26) El-Serag HB1, Tran T, Everhart JE : Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004 ; 126 : 460-8
 
27) Powell EE1, Cooksley WG, Hanson R, et al : The natural history of nonalcoholic steatohepatitis : a follow-up study of forty-two patients for up to 21 years. Hepatology 1990 ; 11 : 74-80
 
28) Hamaguchi E, Takamura T, Sakurai M, et al : Histological course of nonalcoholic fatty liver disease in Japanese patients : tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010 ; 33 : 284-6
 
29) Hotta K, Yoneda M, Hyogo H et al : Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010 ; 11 : 172
PubMed
30) Kawaguchi T, Sumida Y, Umemura A et al : Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012 ; 7 : e38322
PubMed
31) Trepo E, Romeo S, Zucman-Rossi J, et al : PNPLA3 gene in liver diseases. J Hepatol 2016 ; 65 : 399-412
 
32) Imajo K, Fujita K, Yoneda M, et al : Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012 ; 16 : 44-54
 
33) Ota T, Gayet C, Ginsberg HN : Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest 2008 ; 118 : 316-32
 
34) Kubota N, Kubota T, Kajiwara E, et al : Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat Commun 2016 ; 7 : 12977
PubMed
35) Kubota T, Kubota N, Kadowaki T : Imbalanced Insulin Actions in Obesity and Type 2 Diabetes : Key Mouse Models of Insulin Signaling Pathway. Cell Metab 2017 ; 25 : 797-810
 
36) Bedogni G, Bellentani S, Miglioli L, et al : The Fatty Liver Index : a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006 ; 6 : 33
PubMed
37) Calori G, Lattuada G, Ragogna F, et al : Fatty liver index and mortality : the Cremona study in the 15th year of follow-up. Hepatology 2011 ; 54 : 145-52
 
38) Lee JH, Kim D, Kim HJ, et al : Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010 ; 42 : 503-8
PubMed
39) de Ledinghen V, Vergniol J, Foucher J, et al : Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012 ; 32 : 911-8
 
40) Kwok R, Choi KC, Wong GL, et al : Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements : a prospective cohort study. Gut 2016 ; 65 : 1359-68
 
41) 小野正文, 西原利治 : IV. 診断の進め方 : 専門医への紹介のポイント. 日内会誌 2016 ; 105 : 47-55
 
42) Matteoni CA, Younossi ZM, Gramlich T, et al : Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity. Gastroenterology 1999 ; 116 : 1413-9
 
43) Brunt EM1, Janney CG, Di Bisceglie AM, et al : Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 ; 94 : 2467-74
 
44) Kleiner DE, Brunt EM, Van Natta M, et al ; Nonalcoholic Steatohepatitis Clinical Research Network : Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 ; 41 : 1313-21
 
45) Sumida Y, Yoneda M, Hyogo H : Japan Study Group of Nonalcoholic Fatty Liver Disease (JSGNAFLD) : A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011 ; 46 : 257-68
 
46) Nakamura A, Yoneda M, Sumida Y, et al : Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig 2013 ; 4 : 651-8
 
47) Okanoue T, Ebise H, Kai T, et al : A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol 2018 ; 53 : 129-39
 
48) Tada T, Kumada T, Toyoda H, et al : New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Biomarkers 2018 ; 23 : 328-34
 
49) Abe M, Miyake T, Kuno A, et al : Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015 ; 50 : 776-84
 
50) Angulo P, Hui JM, Marchesini G, et al : The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007 ; 45 : 846-54
 
51) Shah AG, Lydecker A, Murray K, et al : Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009 ; 7 : 1104-12
 
52) Chalasani N, Younossi Z, Lavine JE, et al : The diagnosis and management of non-alcoholic fatty liver disease : practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012 ; 55 : 2005-23
 
53) Abe M, Miyake T, Kuno A, et al : Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015 ; 50 : 776-84
 
54) Boursier J, Vergniol J, Guillet A, et al : Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 2016 ; 65 : 570-8
PubMed
55) Imajo K, Kessoku T, Honda Y, et al : Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 2016 ; 150 : 626-37
 
56) Ekstedt M, Franzen LE, Mathiesen UL, et al : Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006 ; 44 : 865-73
 
57) Argo CK, Northup PG, Al-Osaimi AM, et al : Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009 ; 51 : 371-9
 
58) Dong F Zhang Y, Huang Y, et al : Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease : a randomized controlled trial. Sci Rep 2016 ; 6 : 36783
PubMed
59) Promrat K, Kleiner DE, Niemeier HM, et al : Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010 ; 51 : 121-9
PubMed
60) Hashida R, Kawaguchi T, Bekki M, et al : Aerobic vs. resistance exercise in non-alcoholic fatty liver disease : A systematic review. J Hepatol 2017 ; 66 : 142-52
 
61) Nagata N, Xu L, Kohno S, et al : Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice. Diabetes 2017 ; 66 : 1222-36
 
62) Belfort R, Harrison SA, Brown K, et al : A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006 ; 355 : 2297-307
 
63) Sanyal AJ1, Chalasani N, Kowdley KV, et al : Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 ; 362 : 1675-85
 
64) Eguchi Y, Kitajima Y, Hyogo H, et al : Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015 ; 45 : 269-78
 
65) Armstrong MJ, Gaunt P, Aithal GP, et al ; LEAN trial team : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016 ; 387 : 679-90
 
66) Seino Y, Terauchi Y, Osonoi T, et al : Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 2018 ; 20 : 378-88
 
67) Takeda A, Irahara A, Nakano A, et al : The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. Intern Med 2017 ; 56 : 2739-44
 
68) Yamamoto C, Miyoshi H, Ono K, et al : Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 2016 ; 63 : 589-96
 
69) Takase T, Nakamura A, Miyoshi H, et al : Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin : an association with glucose-lowering effects. Endocr J 2017 ; 64 : 363-7
 
70) Ito D, Shimizu S, Inoue K, et al : Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes : A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care 2017 ; 40 : 1364-72
 
71) Kuchay MS, Krishan S, Mishra SK, et al : Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care 2018. doi : 10.2337/dc18-0165. [Epub ahead of print]
 
72) Sumida Y, Yoneda M : Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018 ; 53 : 362-76
 
73) Sjostrom L, Narbro K, Sjostrom CD, et al : Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007 ; 357 : 741-52
 
74) Rubino F, Nathan DM, Eckel RH, et al ; Delegates of the 2nd Diabetes Surgery Summit : Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes : A Joint Statement by International Diabetes Organizations. Diabetes Care 2016 ; 39 : 861-77
 

書評

最近チェックした商品履歴

Loading...